 Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 6 | 7 | | 1996 | 1 | 2 | 3 | | 1997 | 2 | 7 | 9 | | 1998 | 0 | 5 | 5 | | 1999 | 4 | 5 | 9 | | 2000 | 3 | 7 | 10 | | 2001 | 2 | 5 | 7 | | 2002 | 3 | 4 | 7 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 5 | 6 | | 2005 | 4 | 9 | 13 | | 2006 | 3 | 11 | 14 | | 2007 | 7 | 4 | 11 | | 2008 | 9 | 4 | 13 | | 2009 | 11 | 14 | 25 | | 2010 | 13 | 14 | 27 | | 2011 | 12 | 11 | 23 | | 2012 | 13 | 6 | 19 | | 2013 | 14 | 16 | 30 | | 2014 | 33 | 5 | 38 | | 2015 | 13 | 11 | 24 | | 2016 | 14 | 11 | 25 | | 2017 | 27 | 12 | 39 | | 2018 | 27 | 9 | 36 | | 2019 | 36 | 15 | 51 | | 2020 | 22 | 35 | 57 | | 2021 | 19 | 38 | 57 | | 2022 | 6 | 42 | 48 | | 2023 | 0 | 56 | 56 | | 2024 | 21 | 24 | 45 | | 2025 | 35 | 8 | 43 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Pollyea D, Kerre T, Deeren D, Beguin Y, Lin TL, Sallman DA, Anguille S, Blum WG, Flament A, Breman E, Lonez C. Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia. Leukemia. 2025 Dec; 39(12):2907-2915.
-
Polites SF, Aldrink JH, Lautz TB, Vierkant RA, Ragan MV, Reiter A, Chen SY, Kim ES, Rinehardt HN, Malek MM, Fleming AM, Murphy AJ, Roach JP, Radhakrishnan S, Kastenberg ZJ, Piche N, Osman Y, Iii HNL, Tracy ET, Favela J, Le HD, Marquart J, Craig B, Lal DR, Seemann N, Petroze R, Rich BS, Glick RD, Selesner L, Yoo A, Fialkowski E, Brown EG, Boehmer C, Dasgupta R, Langham MR. Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection. Pediatr Blood Cancer. 2025 Dec; 72(12):e32029.
-
Matsuo K, Enserro DM, Wright JD, Roman LD, Powell MA, Miller DS, Nagel CI, Thaker PH, Mannel RS, Stuckey AR, Guntupalli SR, Sukumvanich P, Geller MA, Vargas R, Konecny GE, Warshal DP, Tewari KS, Spirtos NM, Pothuri B, Creasman WT, Mutch DG. Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2025 Oct; 201:184-194.
-
Robin TP, Hu J, Jones BL, Patton T, Diamond JR, Behbakht K, Lefkowits C, Corr BR, Fisher CM. Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer. Gynecol Oncol. 2025 Sep; 200:175-179.
-
Corr BR, Thomas SM, Haight PJ, Stock E, Floyd J, Borden LE, Tunnage I, Secord AA, Arend R, Jackson AL, Wright JD, Konecny G, Castellano T, Ko E, Podwika S, Backes F, Spinosa D, Mullen M, Washington C, Pothuri B, Smitherman C, Harsono AAH, Khadraoui H, Suzuki Y, Salani R, Powell K, Subbarao S, Gaillard S. Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability. Gynecol Oncol. 2025 Oct; 201:69-75.
-
Bunch PM, Aiken AH, Baugnon KL, Bazylewicz M, Chang YS, Hagiwara M, Srinivasan A, Strauss SB, Wicks J, Zander DA, Juliano AF. ACR Neck Imaging Reporting and Data System for MRI Version 2025. J Am Coll Radiol. 2025 Nov; 22(11):1325-1336.
-
Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Marín-Jiménez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD. Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. Cancer Cell. 2025 Aug 11; 43(8):1568-1586.e10.
-
Groisser A, Frantz A, Geller JI, Ortiz MV, Walterhouse D, Ranalli M, Woods-Swafford W, Schoettler P, Garrington T, Mullen EA, Ash S, Bardhan P, Balis F, Dome JS. Anti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms Tumor. Pediatr Blood Cancer. 2025 Oct; 72(10):e31915.
-
Abramson JS, Kamdar M, Liu FF, Crotta A, Previtali A, Klijn SL, Wang P, Zhang Y, Bonner A, Lunning M. Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma. Leuk Lymphoma. 2025 Dec; 66(12):2200-2213.
-
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep; 200:58-67.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|